Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IONIS-STAT3Rx · 1 trial · 3 indications
Highest dose level at which no more than 1 out of 6 patients develops a DLT
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | IONIS-STAT3Rx |
| Name | Type | Description |
|---|---|---|
| IONIS-STAT3Rx | DRUG | Three-hour IV infusions on Cycle 0 Days 1, 3, 5, and weekly three-hour IV infusions in Cycles 1 and beyond, on Days 1, 8, and 15 of each cycle. |
Inclusion Criteria: * Aged 18 years or older * Tumors that are relapsed or refractory to at least 1 prior anti-cancer systemic therapy and for which no standard therapy exists * Expansion cohort only: Advanced lymphoma confirmed by histopathology * Measurable or evaluable disease according to RECIS...
IONIS-STAT3Rx is an investigational drug being developed for the treatment of advanced cancers, including diffuse large B-cell lymphoma (DLBCL) and lymphoma. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
IONIS-STAT3Rx is a small molecule designed to target STAT3, a protein involved in cancer cell growth and survival. By inhibiting STAT3, the drug aims to disrupt signaling pathways that promote tumor progression in advanced cancers.
IONIS-STAT3Rx is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with advanced cancers.
IONIS-STAT3Rx is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied in an early-stage trial to assess its safety, tolerability, and dosing in patients with advanced cancers.
IONIS-STAT3Rx has one completed clinical trial, NCT01563302, a Phase 1/2 open-label, dose-escalation study in patients with advanced cancers, including DLBCL and lymphoma. The trial enrolled 64 participants in the United States and was not randomized or blinded.